Want to see SE:SECARE full AI Analyst Report?
Top Page
Swedencare AB
(SECARE)
Select Model
Select Model
Rating:56Neutral
Price Target:
kr23.00
▼(-1.50% Downside)
Action:Reiterated
Date:07/23/26
The score is supported primarily by solid financial footing (moderate leverage and positive free cash flow) and strong historical revenue scaling. It is held back by sharp margin compression and low returns on equity, while the stock also shows weak technicals (below major moving averages with negative MACD) and an expensive valuation (very high P/E with only a modest dividend yield).
Positive Factors
Revenue Scaling / Top-line Growth
Sustained, multi-year revenue expansion indicates the business is winning distribution and customer adoption across veterinary, retail and e-commerce channels. Durable top-line growth supports economies of scale, funds reinvestment in brands and reduces single-market dependency over a 2–6 month horizon and beyond.
Negative Factors
Sharp Gross-Margin Compression
A sustained drop in gross margin materially reduces the operating leverage that previously amplified revenue growth into profits. If due to structural mix, pricing pressure, or higher COGS, the decline can persist and constrain margin recovery and profitability over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scaling / Top-line Growth
Sustained, multi-year revenue expansion indicates the business is winning distribution and customer adoption across veterinary, retail and e-commerce channels. Durable top-line growth supports economies of scale, funds reinvestment in brands and reduces single-market dependency over a 2–6 month horizon and beyond.
Read all positive factors
Swedencare AB (SECARE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr3.44B
Dividend Yield1.28%
Average Volume (3M)305.00K
Price to Earnings (P/E)43.7
Beta (1Y)0.71
Revenue Growth4.84%
EPS Growth22.61%
CountrySE
Employees624
SectorConsumer Defensive
Sector Strength42
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.50
Shares Outstanding159,840,960
10 Day Avg. Volume222,741
30 Day Avg. Volume305,002
Financial Highlights & Ratios
PEG Ratio-2.52
Price to Book (P/B)0.92
Price to Sales (P/S)2.27
P/FCF Ratio22.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr45.00Price Target Upside92.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.03
Revenue Forecast (FY)kr2.86B
Swedencare AB Business Overview & Revenue Model
Company Description
Swedencare AB (publ), an enterprise established in 1993 and headquartered in Malmö, Sweden, operates with its subsidiaries to develop, produce, market, and sell a wide array of healthcare products, predominantly for animals. The company's flagship...
How the Company Makes Money
Swedencare makes money primarily by selling companion-animal health and wellness products across a portfolio of brands. Revenue is generated from (1) product sales to veterinary channels (e.g., clinics and animal hospitals) where products are reco...
Swedencare AB Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.72B | 2.69B | 2.54B | 2.34B | 1.83B | 770.44M |
| Gross Profit | 1.24B | 1.52B | 1.46B | 1.29B | 1.02B | 385.87M |
| EBITDA | 510.70M | 451.70M | 549.50M | 484.00M | 392.40M | 138.73M |
| Net Income | 80.00M | 55.50M | 98.90M | 58.60M | 94.50M | 54.62M |
Balance Sheet | ||||||
| Total Assets | 9.94B | 9.51B | 10.32B | 9.52B | 10.00B | 3.47B |
| Cash, Cash Equivalents and Short-Term Investments | 85.40M | 103.00M | 186.80M | 237.30M | 245.07M | 136.09M |
| Total Debt | 1.77B | 2.10B | 1.51B | 1.66B | 1.91B | 721.53M |
| Total Liabilities | 2.84B | 2.84B | 2.28B | 2.32B | 2.54B | 1.05B |
| Stockholders Equity | 7.10B | 6.66B | 8.03B | 7.21B | 7.46B | 2.42B |
Cash Flow | ||||||
| Free Cash Flow | 275.20M | 275.60M | 287.80M | 408.00M | 185.51M | 98.06M |
| Operating Cash Flow | 340.70M | 326.80M | 359.10M | 444.00M | 260.20M | 125.85M |
| Investing Cash Flow | -99.00M | -531.40M | -151.90M | -176.40M | -4.67B | -1.87B |
| Financing Cash Flow | -284.70M | 137.80M | -274.20M | -271.60M | 4.49B | 1.59B |
Swedencare AB Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | kr5.14B | 13.42 | 51.57% | 4.64% | 42.70% | 86.19% | |
71 Outperform | kr11.69B | 33.53 | 27.58% | 1.42% | 9.78% | 21.14% | |
63 Neutral | kr1.68B | 15.00 | 3.73% | 2.34% | -2.47% | 460.15% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | kr3.44B | 43.70 | 1.16% | 0.66% | 4.84% | 22.61% | |
56 Neutral | kr4.56B | 531.01 | 8.93% | ― | 15.68% | -89.05% | |
43 Neutral | kr476.97M | -10.49 | ― | ― | 3.26% | 16.82% |
* Consumer Defensive Sector Average
SE:SECARE
Swedencare AB
21.85
-15.66
-41.74%
SE:BIOG.B
BioGaia AB
115.00
22.62
24.48%
SE:ZZ.B
Zinzino AB
137.30
-57.49
-29.51%
SE:MSON.B
Midsona AB Class B
11.55
3.57
44.77%
SE:HAYPP
Haypp Group AB
140.40
-1.60
-1.13%
SE:ENZY
Enzymatica AB
1.95
-0.37
-16.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.